ESC 2023 | FIRE-Trial: Physiology Guided Complete Revascularization Benefits Elderly Patients with Myocardial Infarction

Patients over 75 with acute coronary syndrome (ACS) are often badly represented in most significant studies. 

ESC 2023

In this context, the FIRE study looked to determine whether physiology guided complete revascularization is superior to culprit-only revascularization in elderly patients with multivessel disease suffering acute MI. 

The study included SCA patients over 75, hospitalized for both STEMI and NSTEMI, who had received successful PCI of culprit lesion. These patients also presented multivessel disease with at least one lesion in a non-culprit vessel, minimum 2.5 mm in diameter and obstructed between 50% to 99%. 

After treating the culprit lesion, patients were randomized to culprit only treatment or physiology guided complete revascularization (PCI to lesions with positive functional tests). Primary end point was a composite of events including death, MI, stroke or new ischemia driven revascularization within one year. Secondary end point was a combination of cardiovascular death or MI at one year. Individual primary end components were also looked into. 

Read also: ESC 2023 | BUDAPEST CRT Upgrade trial.

The study looked at 1445 patients from 34 centers in Italy, Spain and Poland. Mean patient age was 80, and 36.5% were women. Primary end point was seen in 15.7% of patients undergoing physiology guided revascularization vs. 21% of patients receiving culprit only treatment (RR 0.73, CI 95%: 0.57-0.93; P=0.01). The number needed to treat (NNT) to prevent an event was 19 patients.

Each of this individual components of the primary end point seemed lower with physiology guided PCI, except for stroke, which resulted in reduced mortality (RR 0.64, CI 95%: 0.51-0.96) and NNT 27 patients to prevent death. There were no differences in safety outcomes. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presentado en Hot Line Sessions, agosto 26, ESC Congress 2023, Amsterdam.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....